ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Simple Search Results

Didn't find what you were looking for? Try the Advanced Search »

  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
Search Again »
  • Abstract Number: 0659 • ACR Convergence 2024

    Obinutuzumab Benefits Patients with Active Lupus Nephritis Irrespective of Baseline Proteinuria Severity: A Post Hoc Analysis of a Phase II Trial

    Richard Furie1, Jorge A. Ross Terres2, Elsa Martins3, Imran Hassan4, Thomas Schindler3, Jay Garg5, William F. Pendergraft III6, Ana Malvar7 and Brad Rovin8, 1Northwell Health, Manhasset, NY, 2Genentech, Inc,, San Francisco, 3F. Hoffmann-La Roche Ltd, Basel, Switzerland, 4Hoffmann-La Roche Ltd, Mississauga, Canada, 5Genentech, Inc., South San Francisco, CA, 6Genentech, Inc., Chapel Hill, NC, 7Organización Médica de Investigación, Buenos Aires, Argentina, 8The Ohio State University, Columbus, OH

    Background/Purpose: Lupus nephritis (LN) is the most common severe organ-threatening manifestation of systemic lupus erythematosus (SLE). The randomized, placebo-controlled, Phase II NOBILITY trial (NCT02550652) demonstrated…
  • Abstract Number: 1495 • ACR Convergence 2024

    Real-World Reduction in Disease Flares and Oral Corticosteroid Use with Anifrolumab Therapy in Systemic Lupus Erythematosus: A Claims-Based Study

    Mawuena Binka1, Rana Muhammad Qasim Khan2, Joseph Tkacz3, Donna McMorrow3, Laurence Gozalo3 and Gail Kerr4, 1BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, 2BioPharmaceuticals Medical, AstraZeneca, Wilmington, 3Inovalon, Bowie, MD, 4Veterans Affairs Medical Center, Georgetown and Howard University Hospitals, Washington, DC

    Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, chronic autoimmune disease characterized by frequent episodes of disease activity (flares) of varying severity.1 SLE flares are…
  • Abstract Number: 1542 • ACR Convergence 2024

    Efficacy and Safety Results from a Phase 2 Trial of Daxdilimab in Patients with Systemic Lupus Erythematosus

    Arezou Khosroshahi1, Sarah Welsh2, Liangwei Wang2, David Larson2 and Nisha Jain2, 1Emory University, Atlanta, GA, 2Amgen, Inc., Rockville, MD

    Background/Purpose: SLE, an autoimmune disease affecting multiple organ systems, is characterized by periods of flares and remission. Type I interferon secreted at high levels by…
  • Abstract Number: 1554 • ACR Convergence 2024

    Belimumab Increases SLE Responder Index-4 Response Rates versus Placebo in Early Active Systemic Lupus Erythematosus: A Large Integrated Analysis of Belimumab Trials

    Karen Costenbader1, Joan Merrill2, Marta Mosca3, Holly Quasny4, Christine Henning5, Steven Bloom6, Julia Harris6, Ciara O’Shea7, Tatsuya Atsumi8 and Ronald van Vollenhoven9, 1Brigham and Women’s Hospital, Division of Rheumatology, Inflammation and Immunity, Harvard Medical School, Boston, MA, 2Oklahoma Medical Research Foundation, Arthritis & Clinical Immunology Program, Oklahoma City, OK, 3University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, 4GSK, Clinical Sciences, Durham, NC, 5GSK, Global Medical Affairs, Durham, NC, 6GSK, Immunology Biostatistics, Brentford, United Kingdom, 7GSK, Rheumatology, Global Medical Affairs, Dublin, Ireland, 8Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, 9Amsterdam Rheumatology and Immunology Center and Amsterdam University Medical Centers, Department of Rheumatology, Amsterdam, Netherlands

    Background/Purpose: There are benefits of early treatment for autoimmune diseases; however, data are not available for patients (pts) with SLE as there is no definition…
  • Abstract Number: 1801 • ACR Convergence 2024

    Inhibitory Effects of Dapirolizumab Pegol, a Monovalent Anti-CD40L PEG-Conjugated Antigen-Binding Fragment Lacking a Functional Fc Domain, on In Vitro T Follicular Helper/B Cell Interactions and Cytokine Production in Systemic Lupus Erythematosus

    Tania Rowley1, Adnan R. Khan1, Laura McLaughlin1, Hannah Cherry1, Farnaz Fallah-Arani1, Yiannis Ioannou1, Debasish Pyne2 and Anthony Shock1, 1UCB Pharma, Slough, United Kingdom, 2Barts Health NHS Trust, London, United Kingdom

    Background/Purpose: The pivotal role of CD40-CD40L interactions in systemic lupus erythematosus (SLE) pathogenesis stems from the orchestration of a range of immune and inflammatory responses…
  • Abstract Number: 2402 • ACR Convergence 2024

    Belimumab Reduces Disease Flares versus Placebo in Adults with Early Active Systemic Lupus Erythematosus: Results of a Large Integrated Analysis

    Marta Mosca1, Karen Costenbader2, Joan Merrill3, Holly Quasny4, Christine Henning5, Steven Bloom6, Julia Harris6, Ciara O’Shea7, Tatsuya Atsumi8 and Ronald Van Vollenhoven9, 1University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy, 2Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, 3Oklahoma Medical Research Foundation, Oklahoma City 73104, OK, 4GSK, Clinical Sciences, Durham, NC, 5GSK, Global Medical Affairs, Durham, NC, 6GSK, Immunology Biostatistics, Brentford, United Kingdom, 7GSK, Rheumatology, Global Medical Affairs, Dublin, Ireland, 8Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, 9Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands

    Background/Purpose: SLE flares are associated with increased risk of organ damage/mortality; flare prevention is a key treatment goal.1 Initiating treatment earlier has benefits in autoimmune…
  • Abstract Number: 2430 • ACR Convergence 2024

    Dapirolizumab Pegol Impacts Important Immunologic Pathways in Systemic Lupus Erythematosus: Pharmacodynamic Analysis of T Cell and Antigen Presenting Cell Pathways from a Phase 2b Trial

    Alex S. Powlesland1, Ioana Cutcutache1, Andrew Skelton1, Anthony Shock1, Matthew Page1, Eris Bame2, Janine Gaiha-Rohrbach2, George Stojan3, Ania Skowera1, Christian Stach4 and Thomas Dörner5, 1UCB Pharma, Slough, United Kingdom, 2Biogen Inc., Cambridge, MA, 3UCB Pharma, Atlanta, GA, 4UCB Pharma, Monheim am Rheim, Germany, 5Department of Medicine, Rheumatology and Clinical Immunology,Charite Universitätsmedizin Berlin, Germany and DRFZ, Berlin, Berlin, Germany

    Background/Purpose: CD40-CD40L interactions play a pivotal role in systemic lupus erythematosus (SLE) pathogenesis by orchestrating a range of immune and inflammatory responses involving B cells,…
  • Abstract Number: 2431 • ACR Convergence 2024

    DORIS Remission in Patients with SLE Treated with Anifrolumab: Post Hoc Analysis from TULIP-1 and TULIP-2 Trials in Patents with No Reported History of Prior Immunosuppressant Use

    doria Andrea1, Ronald Van Vollenhoven2, Eric Morand3, Catharina Lindholm4, Jonatan Hedberg4, Miina Waratani5 and Danuta Kielar6, 1University of Padova, Padova, Italy, 2Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands, 3School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, 4BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, 5Biopharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, 6Biopharmaceuticals Medicine, AstraZeneca, Cambridge, United Kingdom

    Background/Purpose: 2023 EULAR recommendations for the management of SLE open up the option for early treatment initiation with biologics without the requirement to fail immunosuppressants/DMARDs…
  • Abstract Number: 2438 • ACR Convergence 2024

    Reduction in Oral Corticosteroid Use During Anifrolumab Therapy: Observations from a Real-world Cohort of Adults with Systemic Lupus Erythematosus

    Vasileios Kyttaris1, Gelareh Atefi2, Dan Persons3, Dana Withrow3 and Mawuena Binka4, 1BIDMC, Boston, MA, 2AstraZeneca, Media, PA, 3Trio Health, Louisville, CO, USA, Louisville, 4BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE

    Background/Purpose: Oral corticosteroids (OCS) are a mainstay in the clinical management of systemic lupus erythematosus (SLE). However, prolonged use may result in systemic side effects.1…
  • Abstract Number: 0598 • ACR Convergence 2023

    Litifilimab Modulates Type I IFN Biomarkers in Patients with SLE or CLE in the Phase 2 LILAC Study

    Richard Furie1, Victoria Werth2, Eric Milliman3, Kyle Ferber3, Fergal Casey3, Roland Brown3, Denitza Raitcheva3, Jad Zoghbi3, Danielle Graham3, George Kong3, Youmna Lahoud3, Nathalie Franchimont4 and Catherine Barbey5, 1Northwell Health, Manhasset, NY, 2University of Pennsylvania and Corporal Michael J. Crescenz VAMC, Philadelphia, PA, 3Biogen, Cambridge, MA, 4Former employee of Biogen, Cambridge, MA, 5Biogen, Baar, Switzerland

    Background/Purpose: Litifilimab is a humanized IgG1 mAb targeting BDCA2, a receptor expressed on plasmacytoid dendritic cells (pDCs), that negatively regulates the production of Type I…
  • Abstract Number: 0784 • ACR Convergence 2023

    Kidney-Related Outcomes and Steroid-Sparing Effects in Patients with Active Lupus Nephritis Treated with Obinutuzumab: A Post Hoc Analysis of a Phase 2 Trial

    Brad Rovin1, Jorge Ross Terres2, Sophia Giang3, Thomas Schindler4, Armando Turchetta5, Jay Garg2, Richard Furie6, William F. Pendergraft III2 and Ana Malvar7, 1Ohio State University, Columbus, OH, 2Genentech, Inc., South San Francisco, CA, 3Genentech, Inc., San Francisco, CA, 4F. Hoffmann-La Roche Ltd, Basle, Switzerland, 5F. Hoffmann-La Roche Ltd, Basel, Switzerland, 6Northwell Health, Manhasset, NY, 7Hospital Fernandez, Buenos Aires, Argentina

    Background/Purpose: Preservation of long-term kidney function and sustained reduction of glucocorticoid use are major therapeutic goals in lupus nephritis (LN). In the randomized, double-blind, placebo-controlled,…
  • Abstract Number: 1372 • ACR Convergence 2023

    Obinutuzumab Efficacy and Tolerance in Patients with Auto-Immune Diseases Immunized Against Rituximab

    Mathilde Pezot1, Gaetane Nocturne2, Rakiba Belkhir1, Julien Henry1, Stephan Pavy1, Raphaele Seror3, Xavier Mariette4 and Samuel Bitoun5, 1Rheumatology Department, Université Paris-Saclay, INSERM U1184, Hôpital Bicêtre, APHP, FHU CARE, Le Kremlin-Bicêtre, France, 2APHP, Le Kremlin-Bicêtre, France, 3University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, 4Université Paris-Saclay, Le Kremlin-Bicêtre, France, 5CHU Bicêtre APHP, Le Kremlin-Bicêtre, France

    Background/Purpose: Among patients with auto-immune diseases (AID) treated with Rituximab (RTX), anti-drug antibodies (ADAb) leading to inefficacy and infusion reactions (Wincup and al., Ann Rheum…
  • Abstract Number: 1500 • ACR Convergence 2023

    Cumulative Infections by Week 52 Among Patients with SLE: A Summary of Data from Placebo-Controlled Belimumab Studies

    Saira Sheikh1, Kevin Withrop2, Jinoos Yazdany3, Sandra Navarra4, Tatsuya Atsuma5, Paula Curtis6, Jose Miyar Olaiz7, Christine Henning8, Roger A. Levy9, William Stohl10 and Daniel Wallace11, 1University of North Carolina at Chapel Hill, Chapel Hill, NC, 2Oregon Health & Science University, Schools of Medicine and Public Health,, Portland, OR, 3University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, 4University of Santo Tomas Hospital, Joint and Bone Center, Manila, Philippines, 5Hokkaido University, Department of Rheumatology, Endocrinology and Nephrology, Sapporo, Japan, 6GlaxoSmithKline, R&D Biostatistics, Brentford, United Kingdom, 7GlaxoSmithKline, Safety Evaluation and Risk Management, Brentford, United Kingdom, 8GlaxoSmithKline, US Medical Affairs, Durham, NC, 9GlaxoSmithKline, Global Medical Affairs, Collegeville, PA, 10University of Southern California Keck School of Medicine, Division of Rheumatology, Los Angeles, CA, 11Cedars-Sinai Medical Center, Los Angeles, CA

    Background/Purpose: Patients with SLE have a high risk of infections, which remains a common cause of mortality in this population.1 This infection risk can result…
  • Abstract Number: 1503 • ACR Convergence 2023

    Disease Course and Complement as Predictors of Response to Standard of Care Plus Placebo in Patients with SLE: A Post Hoc Analysis of Dapirolizumab Pegol and Epratuzumab Clinical Trial Data

    Christian Stach1, Caroline Gordon2, Vanessa Taieb3, George Stojan4 and Joan Merrill5, 1UCB Pharma, Monheim am Rheim, Germany, 2Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, 3UCB Pharma, Colombes, France, 4UCB, Baltimore, MD, 5Oklahoma Medical Research Foundation, Oklahoma City, OK

    Background/Purpose: High placebo responses pose challenges to systemic lupus erythematosus (SLE) clinical trials.1This analysis aims to identify predictors of standard of care plus placebo (SOC+PBO)…
  • Abstract Number: 2332 • ACR Convergence 2023

    Dapirolizumab Pegol Efficacy by Subgroups in Patients with SLE: A Post Hoc Analysis of Phase 2b Clinical Trial Data

    Anca Askanase1, Christian Stach2, Claire Brittain3, George Stojan4 and Richard Furie5, 1Columbia University Medical Center, New York, NY, 2UCB Pharma, Monheim am Rheim, Germany, 3UCB Pharma, Slough, United Kingdom, 4UCB, Baltimore, MD, 5Northwell Health, Manhasset, NY

    Background/Purpose: Systemic lupus erythematosus (SLE) clinical trials are challenged by high standard of care plus placebo (SOC+PBO) response rates.1 Previous post hoc analyses of the…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
Search Again »

Didn't find what you were looking for? Try the Advanced Search »

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology